Two independent generic Nuvaring approved
says SR. This means there are already 4 available on market. Nuvaring ( original ) and
they have also released their own generic.
. Market Share can only be achieved
with
heavily discounted price. Mayne already
experiences a lot of this in their products.
So why bother ? 2023 appears earliest approval
Thats 6 years of waste of human and financial
resources. Mayne Pharma has been so badly
mismanaged it is shameful and the Board
should be ashamed. Our Credibility is shot
and the majority should resign with embarrassment.
Ann: MAYNE PHARMA provides FDA update on generic NUVARING, page-16
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.48 |
Change
0.070(1.59%) |
Mkt cap ! $381.1M | |||
| Open | High | Low | Value | Volume |
| $4.43 | $4.54 | $4.42 | $1.026M | 230.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 154 | $4.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.50 | 16238 | 2 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |